These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 1384145)
1. The role of cisplatin/bleomycin-based chemotherapy in the treatment of poorly differentiated carcinoma of unknown primary site. Hainsworth JD; Johnson DH; Greco FA Semin Oncol; 1992 Apr; 19(2 Suppl 5):54-7; discussion 58. PubMed ID: 1384145 [TBL] [Abstract][Full Text] [Related]
2. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. Hainsworth JD; Johnson DH; Greco FA J Clin Oncol; 1992 Jun; 10(6):912-22. PubMed ID: 1375284 [TBL] [Abstract][Full Text] [Related]
3. Etoposide/cisplatin-based chemotherapy for patients with metastatic poorly differentiated carcinoma of unknown primary site. Greco FA; Johnson DH; Hainsworth JD Semin Oncol; 1992 Dec; 19(6 Suppl 13):14-8. PubMed ID: 1492223 [TBL] [Abstract][Full Text] [Related]
4. Curative combination chemotherapy for patients with advanced poorly differentiated carcinoma of unknown primary site. Hainsworth JD; Dial TW; Greco FA Am J Clin Oncol; 1988 Apr; 11(2):138-45. PubMed ID: 2451881 [TBL] [Abstract][Full Text] [Related]
5. A randomized trial of cisplatin, vinblastine, and bleomycin versus vinblastine, cisplatin, and etoposide in the treatment of advanced germ cell tumors of the testis: a Southwest Oncology Group study. Wozniak AJ; Samson MK; Shah NT; Crawford ED; Ford CD; Altman SJ; Stephens RL; Natale RB; Bouroncle BA; Blumenstein BA J Clin Oncol; 1991 Jan; 9(1):70-6. PubMed ID: 1702148 [TBL] [Abstract][Full Text] [Related]
6. The role of etoposide in the treatment of poorly differentiated carcinoma of unknown primary site. Hainsworth JD; Johnson DH; Greco FA Cancer; 1991 Jan; 67(1 Suppl):310-4. PubMed ID: 1984833 [TBL] [Abstract][Full Text] [Related]
7. Combination chemotherapy with vinblastine, bleomycin, cisplatin, and etoposide (VBPE) in children with primary intracranial germ cell tumors. Chang TK; Wong TT; Hwang B Med Pediatr Oncol; 1995 Jun; 24(6):368-72. PubMed ID: 7536294 [TBL] [Abstract][Full Text] [Related]
8. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide. Hainsworth JD; Erland JB; Kalman LA; Schreeder MT; Greco FA J Clin Oncol; 1997 Jun; 15(6):2385-93. PubMed ID: 9196154 [TBL] [Abstract][Full Text] [Related]
10. The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. Australasian Germ Cell Trial Group. Levi JA; Raghavan D; Harvey V; Thompson D; Sandeman T; Gill G; Stuart-Harris R; Snyder R; Byrne M; Kerestes Z J Clin Oncol; 1993 Jul; 11(7):1300-5. PubMed ID: 7686216 [TBL] [Abstract][Full Text] [Related]
11. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Loehrer PJ; Lauer R; Roth BJ; Williams SD; Kalasinski LA; Einhorn LH Ann Intern Med; 1988 Oct; 109(7):540-6. PubMed ID: 2844110 [TBL] [Abstract][Full Text] [Related]
12. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy. Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521 [TBL] [Abstract][Full Text] [Related]
13. Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site. van der Gaast A; Verweij J; Planting AS; Hop WC; Stoter G J Clin Oncol; 1995 Jul; 13(7):1720-5. PubMed ID: 7541451 [TBL] [Abstract][Full Text] [Related]
14. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. Williams SD; Birch R; Einhorn LH; Irwin L; Greco FA; Loehrer PJ N Engl J Med; 1987 Jun; 316(23):1435-40. PubMed ID: 2437455 [TBL] [Abstract][Full Text] [Related]
15. Taxane-based chemotherapy for patients with carcinoma of unknown primary site. Greco FA; Gray J; Burris HA; Erland JB; Morrissey LH; Hainsworth JD Cancer J; 2001; 7(3):203-12. PubMed ID: 11419028 [TBL] [Abstract][Full Text] [Related]
16. Multicentric phase II study of cisplatin and etoposide in patients with metastatic carcinoma of unknown primary. Voog E; Merrouche Y; Trillet-Lenoir V; Lasset C; Peaud PY; Rebattu P; Negrier S Am J Clin Oncol; 2000 Dec; 23(6):614-6. PubMed ID: 11202809 [TBL] [Abstract][Full Text] [Related]
17. Treatment of poor-prognosis sex cord-stromal tumors of the ovary with the combination of bleomycin, etoposide, and cisplatin. Gershenson DM; Morris M; Burke TW; Levenback C; Matthews CM; Wharton JT Obstet Gynecol; 1996 Apr; 87(4):527-31. PubMed ID: 8602303 [TBL] [Abstract][Full Text] [Related]
18. Successful treatment of metastatic thymic carcinoma with cisplatin, vinblastine, bleomycin, and etoposide chemotherapy. Carlson RW; Dorfman RF; Sikic BI Cancer; 1990 Nov; 66(10):2092-4. PubMed ID: 1699650 [TBL] [Abstract][Full Text] [Related]
19. A phase II trial of VP-16, ifosfamide, cisplatin, vinblastine, and bleomycin in advanced germ-cell tumors. Blanke C; Loehrer PJ; Nichols CR; Einhorn LH Am J Clin Oncol; 1996 Oct; 19(5):487-91. PubMed ID: 8823477 [TBL] [Abstract][Full Text] [Related]
20. Treatment of recurrent and metastatic head and neck cancer with cisplatin/etoposide/bleomycin. Osoba D; Band PR; Connors JM; Goldie JH; Knowling MA; Fetherstonhaugh EM Semin Oncol; 1992 Apr; 19(2 Suppl 5):25-9; discussion 30-1. PubMed ID: 1384140 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]